Table 2.

Pearson’s correlation between composite ratios and cumulative scores and baseline clinicopathological characteristics of patients with multiple myeloma undergoing autologous hematopoietic stem cell transplantation (HSCT) (n = 224).

	Age	Sex	BMI	B Symptoms	ECOG	LDH	CCI	S&D	R-ISS
NLR	0.654	0.354	0.499	0.047	0.164	<0.0001	0.2265	0.535	0.135
NLS	0.951	0.566	0.836	0.023	0.077	0.0006	0.001	0.115	0.223
PLR	0.269	0.183	0.611	0.401	0.638	0.79	0.443	0.731	0.370
PLS	0.837	0.438	0.405	0.101	0.361	0.079	0.044	0.145	0.517
NPS	0.951	0.531	0.853	<0.0001	0.051	<0.0001	0.067	0.879	0.018
CAR	0.195	0.685	0.335	<0.0001	<0.0001	<0.0001	<0.0001	0.054	0.0003
PI	0.005	0.857	0.246	<0.0001	<0.0001	<0.0001	<0.0001	0.038	<0.0001
PNI	0.119	0.951	0.876	0.002	<0.0001	<0.0001	<0.0001	0.856	0.0002
HR-CC	0.626	0.051	0.386	0.008	0.035	0.009	0.164	0.016	<0.0001
GPS	0.015	0.594	0.17	0.0004	<0.0001	<0.0001	<0.0001	0.097	<0.0001

* p < 0.05 is considered significant. Significant results are highlighted in bold. BMI, body mass index; CAR, C-reactive protein albumin ratio; HR-CC, high-risk cytogenetic changes; CCI, Charlson Comorbidity Index; ECOG, Eastern Cooperative Oncology Group; GPS, Glasgow Prognostic Score; ISS, International Staging System; LDH, lactate-dehydrogenase; NLR, neutrophil–lymphocyte ratio; NLS, neutrophil–lymphocyte score; NPS, neutrophil–platelet score; PI, Prognostic Index; PLR, platelet–lymphocyte ratio; PLS, platelet–lymphocyte score; R-ISS, Revised International Staging System; S&D, Salmon and Durie.